EGFR and non-small cell lung carcinoma: An implication of these findings is the possibility that advanced NSCLC patients with T790M mutation-positive tumors obtained more clinical benefits from Osimertinib than those with tumors with the Ex19del and/or L858R mutation, suggesting that the EGFR mutation status of patients should be determined before starting treatment.